Howard M. Stern

11.8k total citations · 1 hit paper
67 papers, 5.0k citations indexed

About

Howard M. Stern is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Howard M. Stern has authored 67 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 26 papers in Oncology and 14 papers in Genetics. Recurrent topics in Howard M. Stern's work include Chronic Lymphocytic Leukemia Research (14 papers), HER2/EGFR in Cancer Research (12 papers) and Lymphoma Diagnosis and Treatment (11 papers). Howard M. Stern is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), HER2/EGFR in Cancer Research (12 papers) and Lymphoma Diagnosis and Treatment (11 papers). Howard M. Stern collaborates with scholars based in United States, France and Belgium. Howard M. Stern's co-authors include Leonard I. Zon, Stephen D. Hauschka, Klaus P. Hoeflich, Jennifer L. Shepard, James F. Amatruda, Thinh Q. Pham, Xander Munroe, Mark X. Sliwkowski, Evelyn Yao and Lisa Crocker and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Howard M. Stern

67 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy

2008 501 citations Si Tuen Lee-Hoeflich, Lisa Crocker et al. Cancer Research profile →

Peers

Countries citing papers authored by Howard M. Stern

Since Specialization

Citations

This map shows the geographic impact of Howard M. Stern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard M. Stern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard M. Stern more than expected).

Fields of papers citing papers by Howard M. Stern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard M. Stern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard M. Stern. The network helps show where Howard M. Stern may publish in the future.

Co-authorship network of co-authors of Howard M. Stern

This figure shows the co-authorship network connecting the top 25 collaborators of Howard M. Stern. A scholar is included among the top collaborators of Howard M. Stern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard M. Stern. Howard M. Stern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Predicting Clinical Response and Safety of JCAR017 in B-NHL Patients: Potential Importance of Tumor Microenvironment Biomarkers and CAR T-Cell Tumor Infiltration 2017 ·Blood ·Christina Swanson, Trevor Do, (unknown), (unknown), (unknown), (unknown), (unknown), Claire L. Sutherland, Benhuai Xie, (unknown), Daniel Li, Tina Albertson, Howard M. Stern, (unknown)	6
2	Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma 2017 ·Blood ·Steven M. Horwitz, Raphael Koch, Pierluigi Porcu, Yasuhiro Oki, Alison J. Moskowitz, Megan N. Perez, Patricia L. Myskowski, Adam Officer, Jacob D. Jaffe, Sara Morrow, Kerstin Allen, Mark Douglas, Howard M. Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Jon C. Aster, David T. Weaver, Francine M. Foss, David M. Weinstock	204
3	PTEN Loss Is Associated with Worse Outcome in HER2 -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance 2015 ·Clinical Cancer Research ·Howard M. Stern, Humphrey Gardner, Tomasz Burzykowski, Wafaa Elatre, Carol O’Brien, Mark R. Lackner, Gary A. Pestano, Angela Santiago, Ivonne Villalobos, W. Eiermann, Tadeusz Pieńkowski, Miguel Martín, Nicholas J. Robert, John Crown, Paolo Nucíforo, Valerie Bée, John R. Mackey, Dennis J. Slamon, Michael F. Press	57
4	Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass 2015 ·Cell Reports ·Mark J. Solloway, Azadeh Madjidi, Chunyan Gu, Jeff Eastham-Anderson, Holly J. Clarke, Noelyn M. Kljavin, Jose Zavala‐Solorio, Lance Kates, Brad A. Friedman, Matt Brauer, Jianyong Wang, Oliver Fiehn, Ganesh Kolumam, Howard M. Stern, John B. Lowe, Andrew S. Peterson, Bernard B. Allan	144
5	Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes 2014 ·Cancer Research ·Genee Y. Lee, Peter M. Haverty, Li Li, Noelyn M. Kljavin, Richard Bourgon, James Lee, Howard M. Stern, Zora Modrušan, Somasekar Seshagiri, Zemin Zhang, (unknown), David Stokoe, Jeffrey Settleman, Frédéric J. de Sauvage, Richard M. Neve	125
6	HSP90 Inhibition Enhances Antimitotic Drug-Induced Mitotic Arrest and Cell Death in Preclinical Models of Non-Small Cell Lung Cancer 2014 ·PLoS ONE ·Brenda O’Connell, Katie O’Callaghan, Bonnie Tillotson, Mark Douglas, Nafeeza Hafeez, Kip A. West, Howard M. Stern, Janid A. Ali, Paul S. Changelian, Christian Fritz, Vito J. Palombella, Karen McGovern, Jeffery L. Kutok	14
7	DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer 2012 ·Clinical Cancer Research ·Walter Kim, Thomas Holcomb, Tom Januario, Pan Du, Marie Evangelista, (unknown), Leonardo Iniguez, Robert Soriano, Ling Huw, Howard M. Stern, Zora Modrušan, Somasekar Seshagiri, Garret M. Hampton, Lukas C. Amler, Richard Bourgon, Robert L. Yauch, David S. Shames	66
8	Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer 2012 ·Cancer Investigation ·Caio M. Rocha Lima, Soley Bayraktar, (unknown), Jessica MacIntyre, Alberto J. Montero, Joaquina Baranda, John M. Wallmark, Chia C. Portera, Rajiv Raja, Howard M. Stern, Stephanie Royer‐Joo, Lukas C. Amler	33
9	Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab 2010 ·Clinical Cancer Research ·Howard M. Stern, (unknown), Klaus W. Wagner, Lukas C. Amler, Avi Ashkenazi	33
10	Oncogenic Activating Mutations Are Associated with Local Copy Gain 2009 ·Molecular Cancer Research ·Barmak Modrek, Lin Ge, Ajay Pandita, Eva Lin, Sankar Mohan, Peng Yue, Steve Guerrero, William M. Lin, Thinh Q. Pham, Zora Modrušan, Somasekar Seshagiri, Howard M. Stern, Paul Waring, Levi A. Garraway, John Chant, David Stokoe, Guy Cavet	51
11	Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes 2009 ·Molecular Cancer Research ·Xiaolan Hu, Howard M. Stern, Lin Ge, Carol O’Brien, Lauren E. Haydu, (unknown), Peter M. Haverty, Brock A. Peters, Thomas D. Wu, Lukas C. Amler, John Chant, David Stokoe, Mark R. Lackner, Guy Cavet	177
12	Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression 2009 ·Cancer Research ·Klaus P. Hoeflich, Sylvia Herter, Janet Tien, Leo Lap-Yan Wong, Leanne Berry, Jocelyn Chan, Carol O’Brien, Zora Modrušan, Somasekar Seshagiri, Mark R. Lackner, Howard M. Stern, Edna F. Choo, Lesley Murray, Lori S. Friedman, Marcia Belvin	144
13	Abstract #LB-131: Biomarker evaluation in the Phase III, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes 2009 ·Cancer Research ·Roy S. Herbst, Howard M. Stern, Lukas C. Amler, Gregory A. Otterson, Ming Lin, Paula G. O’Connor, John D. Hainsworth	1
14	A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy breakdown → 2008 ·Cancer Research ·Si Tuen Lee-Hoeflich, Lisa Crocker, Evelyn Yao, Thinh Q. Pham, Xander Munroe, Klaus P. Hoeflich, Mark X. Sliwkowski, Howard M. Stern	501
15	Construction and application of a zebrafish array comparative genomic hybridization platform 2008 ·Genes Chromosomes and Cancer ·Jennifer L. Freeman, Craig J. Ceol, Hui Feng, David M. Langenau, Cassandra D. Belair, Howard M. Stern, Anhua Song, Barry H. Paw, A. Thomas Look, Yi Zhou, Leonard I. Zon, Charles Lee	18
16	Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models 2006 ·Cancer Research ·Klaus P. Hoeflich, Daniel C. Gray, Michael Eby, Janet Tien, Leo Lap-Yan Wong, (unknown), Alvin Gogineni, Jiping Zha, Mary J. Cole, Howard M. Stern, Lesley Murray, David P. Davis, Somasekar Seshagiri	185
17	Functional characterization of the Bcl-2 gene family in the zebrafish 2006 ·Cell Death and Differentiation ·Erica Kratz, Peter M. Eimon, Kiran Mukhyala, Howard M. Stern, J. Zha, Andreas Strasser, Reece K. Hart, Avi Ashkenazi	118
18	Analysis of the Cell Cycle in Zebrafish Embryos 2004 ·Methods in cell biology ·Jennifer L. Shepard, Howard M. Stern, Kathleen L. Pfaff, James F. Amatruda	41
19	The Zon Laboratory Guide to Positional Cloning in Zebrafish 2004 ·Methods in cell biology ·Nathan Bahary, Alan J. Davidson, David G. Ransom, (unknown), Howard M. Stern, Nikolaus S. Trede, Yi Zhou, Bruce Barut, Leonard I. Zon	62
20	Neural Tube and Notochord Promote in Vitro Myogenesis in Single Somite Explants 1995 ·Developmental Biology ·Howard M. Stern, Stephen D. Hauschka	90

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact